-
公开(公告)号：US10857105B2
公开(公告)日：2020-12-08
申请号：US16382423
申请日：2019-04-12
Applicant: ModernaTX, Inc.
Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
-
公开(公告)号：US10322091B2
公开(公告)日：2019-06-18
申请号：US16219418
申请日：2018-12-13
Applicant: ModernaTX, Inc.
Inventor： Joshua Frederick , Ailin Bai , Vladimir Presnyak , Stephen Hoge , Kerry Benenato , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe , Susannah Hewitt
IPC: A61K48/00 , A61K9/51 , A61K38/17 , A61K38/20 , A61K9/00 , A61K39/39 , A61K45/06 , A61K9/127 , C07K14/54 , C07K14/545 , C07K14/705 , A61P35/00 , A61K39/395 , A61K39/00 , B82Y5/00 , C12N15/88
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
公开(公告)号：US20190105281A1
公开(公告)日：2019-04-11
申请号：US16222155
申请日：2018-12-17
Applicant: ModernaTX, Inc.
Inventor： Joshua Frederick , Ailin Bai , Vladimir Presnyak , Stephen Hoge , Kerry Benenato , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe , Susannah Hewitt
IPC: A61K9/51 , A61K9/00 , C07K14/54 , A61K38/17 , A61K38/20 , C07K14/705 , A61P35/00 , A61K39/395
CPC classification number: A61K9/5123 , A61K9/00 , A61K9/0019 , A61K9/1272 , A61K9/5146 , A61K38/177 , A61K38/1774 , A61K38/20 , A61K38/2006 , A61K38/208 , A61K38/2086 , A61K39/39 , A61K39/3955 , A61K45/06 , A61K48/00 , A61K48/005 , A61K2039/505 , A61K2039/51 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/585 , A61P35/00 , B82Y5/00 , C07K14/54 , C07K14/5434 , C07K14/5443 , C07K14/5446 , C07K14/545 , C07K14/70575 , C07K2319/00 , C12N15/88 , A61K2300/00
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
公开(公告)号：US12123030B2
公开(公告)日：2024-10-22
申请号：US16302368
申请日：2017-05-18
Applicant: ModernaTX, Inc.
Inventor： Kerry Benenato , Stephen Hoge , Paolo Martini , Iain McFadyen , Vladimir Presnyak , Ellalahewage Sathyajith Kumarasinghe
CPC classification number: C12N9/20 , A61K9/1274 , A61K9/5123 , A61K47/14 , B82Y5/00 , B82Y30/00 , C12Y301/01034
Abstract: The invention relates to mRNA therapy for the treatment of hyperlipidemia. mRNAs for use in the invention, when administered in vivo, encode human lipoprotein lipase (LPL), isoforms thereof, functional fragments thereof, and fusion proteins comprising LPL. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto, mRNA therapies of the invention increase and/or restore deficient levels of LPL expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of triglycerides associated with deficient LPL activity in subjects.
-
公开(公告)号：US11571463B2
公开(公告)日：2023-02-07
申请号：US17721583
申请日：2022-04-15
Applicant: ModernaTX, Inc.
Inventor： Joshua Frederick , Susannah Hewitt , Ailin Bai , Stephen Hoge , Vladimir Presnyak , Iain James McFadyen , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
IPC: A61K48/00 , A61K38/20 , A61K9/51 , C07K14/54 , A61K31/7088 , A61K31/7115 , C12N15/62 , A61P35/00 , A61K9/00
Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.
-
Patent Agency Ranking
公开(公告)号：US11344504B1
公开(公告)日：2022-05-31
申请号：US17352904
申请日：2021-06-21
Applicant: ModernaTX, Inc.
Inventor： Joshua P. Frederick , Ailin Bai , Vladimir Presnyak , Stephen G. Hoge , Kerry Benenato , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe , Susannah Hewitt
IPC: A61K38/20 , A61K9/51 , A61K48/00 , A61K38/17 , A61K9/00 , A61K39/39 , A61K45/06 , A61K9/127 , C07K14/54 , C07K14/545 , C07K14/705 , A61K31/7088 , A61K31/7115 , A61P35/00 , A61K39/395 , A61K39/00 , B82Y5/00 , C12N15/88
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
公开(公告)号：US11311602B2
公开(公告)日：2022-04-26
申请号：US17308686
申请日：2021-05-05
Applicant: ModernaTX, Inc.
Inventor： Joshua Frederick , Susannah Hewitt , Ailin Bai , Stephen Hoge , Vladimir Presnyak , Iain McFadyen , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
IPC: A61K48/00 , A61K38/20 , A61K9/51 , C07K14/54 , A61K31/7088 , A61K31/7115 , C12N15/62 , A61P35/00 , A61K9/00
Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.
-
公开(公告)号：US11000573B2
公开(公告)日：2021-05-11
申请号：US16842300
申请日：2020-04-07
Applicant: ModernaTX, Inc.
Inventor： Joshua Frederick , Susannah Hewitt , Ailin Bai , Stephen Hoge , Vladimir Presnyak , Iain McFadyen , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
IPC: A61K48/00 , A61K38/20 , A61K9/51 , C07K14/54 , A61K31/7088 , A61K31/7115 , C12N15/62 , A61P35/00 , A61K9/00
Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.
-
公开(公告)号：US10973917B2
公开(公告)日：2021-04-13
申请号：US16457300
申请日：2019-06-28
Applicant: ModernaTX, Inc.
Inventor： Joshua P. Frederick , Susannah Hewitt , Ailin Bai , Stephen G. Hoge , Vladimir Presnyak , Iain McFadyen , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
IPC: A61K48/00 , A61K39/395 , C07K14/54 , C07K14/705 , C07K16/28 , A61K39/39 , A61K45/06 , A61K31/713 , A61K39/00 , A61P35/00
Abstract: The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.
-
公开(公告)号：US10646549B2
公开(公告)日：2020-05-12
申请号：US16192274
申请日：2018-11-15
Applicant: ModernaTX, Inc.
Inventor： Joshua Frederick , Susannah Hewitt , Ailin Bai , Stephen Hoge , Vladimir Presnyak , Iain Mcfadyen , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.
-
-
-
-
-
-
-
-
-
Search Results
50
records
(took 0.044 seconds)
